Sort by
Medicine and Dentistry
Circulating Tumor DNA
93%
Breast Cancer
84%
Neoplasm
57%
Recurrent Disease
38%
Biological Marker
35%
Minimal Residual Disease
29%
Triple Negative Breast Cancer
29%
Malignant Neoplasm
27%
Hormone Receptor
22%
Overall Survival
21%
Cancer
19%
Diseases
19%
Metastatic Breast Cancer
18%
Neoadjuvant Therapy
15%
Neoadjuvant Chemotherapy
15%
Circulating Tumor Cell
15%
Gamma Urogastrone
15%
Epidermal Growth Factor Receptor 2
15%
Hazard Ratio
14%
Metastatic Carcinoma
14%
Recurrence Free Survival
14%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
13%
DNA Determination
13%
Cell-Free DNA
13%
Progression Free Survival
11%
Phase II Trials
11%
Early Cancer Detection
11%
Adjuvant Therapy
10%
Clinical Trial
10%
Disease Free Survival
10%
Brain Metastasis
10%
Estrogen Receptor
9%
Trastuzumab
9%
Arm
9%
Chloroplast DNA
9%
Breast Tumor
8%
Hormone Therapy
8%
Adjuvant Chemotherapy
8%
Colorectal Carcinoma
7%
Paclitaxel
7%
Lung Cancer
7%
Cholangiocarcinoma
7%
Methylation
6%
Systemic Therapy
6%
Uterine Cancer
6%
Treatment Response
6%
Event Free Survival
6%
Risk Stratification
6%
Randomized Clinical Trial
6%
Radiation Therapy
5%
Keyphrases
Circulating Tumor DNA (ctDNA)
100%
Breast Cancer
44%
Minimal Residual Disease
29%
Pathological Complete Response
28%
Triple-negative Breast Cancer
27%
Metastatic Breast Cancer
26%
Overall Survival
23%
Early Breast Cancer
21%
Tumor-informed
20%
Hormone Receptor-positive
18%
Human Epidermal Growth Factor Receptor 2 (HER2)
18%
Tumor
17%
Circulating Tumor Cells
16%
Early Cancer Detection
16%
Paclitaxel
15%
Cell-free DNA (cfDNA)
15%
Phase II Trial
15%
Neoadjuvant Chemotherapy
15%
Neoadjuvant Therapy
15%
Hazard Ratio
14%
I-SPY
14%
Trastuzumab
14%
Disease-free Survival
13%
Neoadjuvant
13%
Recurrence-free Survival
13%
Detection Test
11%
DNA Assay
11%
Chemotherapy
11%
Adjuvant Chemotherapy
10%
Progression-free Survival
10%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
10%
Colorectal Cancer
10%
Metastatic Triple-negative Breast Cancer
9%
Stage II-III
9%
Randomized Clinical Trial
9%
Brain Metastases
8%
Residual Cancer Burden
8%
Predictive Biomarker
8%
Estrogen Receptor
8%
Breast Cancer Patients
8%
HER2-positive
8%
Endocrine Therapy
8%
Confidence Interval
8%
Disease Diagnosis
8%
Programmed Death-ligand 1 (PD-L1)
8%
Breast Tumor
8%
Clinical Utility
7%
High Risk
7%
DNA Detection
7%
Phase II Study
7%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
59%
Neoplasm
59%
Circulating Tumor DNA
58%
Chemotherapy
27%
Recurrent Disease
26%
Metastatic Breast Cancer
24%
Malignant Neoplasm
22%
Overall Survival
21%
Biological Marker
20%
Triple Negative Breast Cancer
20%
Hormone Receptor
19%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
17%
Diseases
16%
Minimal Residual Disease
15%
Paclitaxel
14%
Progression Free Survival
14%
Recurrence Free Survival
13%
Estrogen Receptor
12%
Phase II Trials
11%
Trastuzumab
11%
Clinical Trial
11%
Disease Free Survival
10%
Gamma Urogastrone
10%
Epidermal Growth Factor Receptor 2
10%
Brain Metastasis
9%
Randomized Clinical Trial
8%
Chloroplast DNA
8%
Trastuzumab Emtansine
7%
Endocrine Therapy
6%
Pembrolizumab
6%
Tamoxifen
5%
Solid Malignant Neoplasm
5%
Alisertib
5%
Early Cancer
5%
Bile Duct Carcinoma
5%
Rectum Cancer
5%
Immunotherapy
5%